These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38981691)

  • 21. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of cirrhosis.
    Sherman MS; Challa PK; Przybyszewski EM; Wilechansky RM; Uche-Anya EN; Ott AT; McGoldrick J; Goessling W; Khalili H; Simon TG
    Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38551386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Dysfunction-Associated Steatotic Liver Disease in Severe Obesity and Concordance between Invasive (Biopsy) and Noninvasive (OWLiver®) Diagnoses.
    Navarro-Masip È; Mestres Petit N; Salinas-Roca B; Herrerías F; Vilardell F; de la Fuente MC; Pallares J; Santamaría M; Zorzano-Martínez M; Sánchez E; Matías-Guiu X; López-Cano C; Soler AG; León-Mengíbar J; Bueno M; Lecube A
    Obes Facts; 2024; 17(5):473-482. PubMed ID: 38934179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
    Marti-Aguado D; Arnouk J; Liang JX; Lara-Romero C; Behari J; Furlan A; Jimenez-Pastor A; Ten-Esteve A; Alfaro-Cervello C; Bauza M; Gallen-Peris A; Gimeno-Torres M; Merino-Murgui V; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández-Izquierdo A; Aguilera V; Giesteira B; França M; Monton C; Escudero-García D; Alberich-Bayarri Á; Serra MA; Bataller R; Romero-Gomez M; Marti-Bonmati L
    Liver Int; 2024 Jan; 44(1):202-213. PubMed ID: 37904633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?
    McPherson S; Dyson JK; Jopson L; Masson S; Patel P; Anstee QM
    Aliment Pharmacol Ther; 2024 Jul; 60(2):267-273. PubMed ID: 38860621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
    Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
    Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis.
    Mózes FE; Lee JA; Vali Y; Selvaraj EA; Jayaswal ANA; Boursier J; de Lédinghen V; Lupșor-Platon M; Yilmaz Y; Chan WK; Mahadeva S; Karlas T; Wiegand J; Shalimar ; Tsochatzis E; Liguori A; Wong VW; Lee DH; Holleboom AG; van Dijk AM; Mak AL; Hagström H; Akbari C; Hirooka M; Lee DH; Kim W; Okanoue T; Shima T; Nakajima A; Yoneda M; Thuluvath PJ; Li F; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Fournier-Poizat C; Geier A; Tuthill T; Yunis C; Anstee QM; Harrison SA; Bossuyt PM; Pavlides M
    Liver Int; 2024 Aug; 44(8):1872-1885. PubMed ID: 38573034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver Tissue Proteins Improve the Accuracy of Plasma Proteins as Biomarkers in Diagnosing Metabolic Dysfunction-Associated Steatohepatitis.
    Sourianarayanane A; Salemi MR; Phinney BS; McCullough AJ
    Proteomics Clin Appl; 2024 Jul; ():e202300236. PubMed ID: 39073724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?
    Tulone A; Pennisi G; Ciccioli C; Infantino G; La Mantia C; Cannella R; Mercurio F; Petta S
    United European Gastroenterol J; 2024 Jun; 12(5):638-648. PubMed ID: 38659291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
    Kokkorakis M; Muzurović E; Volčanšek Š; Chakhtoura M; Hill MA; Mikhailidis DP; Mantzoros CS
    Pharmacol Rev; 2024 May; 76(3):454-499. PubMed ID: 38697855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.